Skip to main content Accessibility help
×
Home
  • Print publication year: 2015
  • Online publication date: April 2015

Section 3 - Gynecological infectious disease

References

1. KloosWE. Ecology of the human skin. In MardhPA, SchleiferKH (eds.) Coagulase-negative Staphylococci. Stockholm: Almquist and Wiksell International, 1986, pp. 37–60.
2. KloosWE, MusselwhiteMS. Distribution and persistence of Staphylococcus and Micrococcus species and other aerobic bacteria of human skin. Appl Microbiol 1975;30:381–385.
3. Wald VogelFA. Staphylococcus aureus (including staphylococcal toxic shock). In MandellGL, BennettJE, DolinR (eds.) Principles and Practice of Infectious Diseases. Philadelphia, PA: Churchill Livingstone, 2000, p. 2079.
4. FeingoldDS. Staphylococcal and streptococcal pyodermas. Semin Dermatol 1993;12:331–335.
5. BisnoAL, StevensDL. Streptococcal infections of the skin and soft tissues. N Engl J Med 1996;34:229–234.
6. FowlerJF Jr: Stage CGC III: Hot tub (Pseudomonas) folliculitis. J Ky Med Assoc 1990;88:66–68.
7. JemecGB, HeidenheimM, NielsonNH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996;35:191–194.
8. SladeDE, PowellBW, MortimerPS. Hidradenitis suppurativa pathogenesis management. Br J Plast Surg 2003;56:451–461.
9. Von Der WerthLM, WilliamsHC, RaeburnJA. The clinical genetics of hidradenitis suppurativa revisited. Br J Dermatol 2000;142:947–953.
10. BrookI, FrazierEH. Aerobic and anaerobic microbiology of axillary hidradenitis suppurativa. J Med Microbiol 1999;48:103–105.
11. LapinsJ, JarstrandC, EmtestamL. Coagulase-negative staphylococci are the most common bacteria found in cultures from deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol 1999;140:90–95.
12. JemecGB, FaberM, GutschikE, WendelboeP. The bacteriology of hidradenitis suppurativa. Dermatology 1996;193:203–206.
13. DickenCH, PowellST, SpearKL. Evaluation of isotretinoin treatment of hidradenitis suppurativa. J Am Acad Derematol 1984;11:500–502.
14. ChowET, MortimerPS. Successful treatment of hidradenitis suppurativa and retroauricular acne with etretinate. Br J Dermatol 1992;126:415–418.
15. JemerGB, GniadeckaM. Sebum excretion in hidradenitis suppurativa. Dermatology 1997;194:325–328.
16. BoerJ, van GemertMJ. Long term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol 1999;40:73–76.
17. AgnholtJ, DahlerupJF, KaltoftK. The effect of Etanercept and infliximab on the production of tumor necrosis factor alpha, interferon-gamma and GM-CSF in in-vivo activated intestinal T lymphocyte cultures. Cytokine 2003;23:76–85.
18. SullivanTP, WelshE, KerdalFA, et al. Infliximab for hidradenitis suppurativa. Br J Dermatol 2003;149:1046–1049.
19. BanjreeAK. Surgical treatment for hidradenitis suppurativa. Br J Surg 1992;79:863–866.
20. HarrisonBJ, MudgeM, HughesLE. Recurrence after surgical treatment of hidradenitis suppurativa. BMJ Clin Res Ed 1987;294:487–489.
21. RompelR, PetresJ. Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg 2000;2 6:638–643.
22. CosmanRC, O'GradyTC, PekarskeS. Verrucous carcinoma arising in hidradenitis suppurativa. Int J Colorectal Dis 2000;15:342–346.
23. ManolitsasT, BiankinS, JaworskiR, WainG. Vulvar squamous cell carcinoma arising in chronic hidradenitis suppurativa. Gynecol Oncol 1999;75:285–288.
24. HurleyR, DeLouvoisJ. Candida vaginitis. Postgrad Med J 1979;55:645–647.
25. SobelJD. Pathogenesis of Candida vulvovaginitis. Curr Top Med Mycol 1989;3:86–108.
26. GeigerAm, FoxmanB. Risk factors in vulvovaginal candidiasis: a case control study among university students. Epidemiology 1996;7:182–187.
27. SobelJD. Candidal vulvovaginitis. Clin Obstet Gynecol 1993;36:153–165.
28. FaroS. Systemic versus topical therapy for the treatment of vulvovaginal candidiasis. Infect Dis Obstet Gynecol 1993;1:202–208.
29. OddsFC. Candida and Candidosis. London: Balliere-Tindall, 1988, pp. 104–110.
30. FleuryFJ. Adult vaginitis. Clin Obstet Gynecol 1981;24:407–438.
31. SobelJD, FaroS, ForceRW, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998;178:203–211.
32. ScudamoreJA, TooleyPJ, AllcornRJ. The treatment of acute and chronic vaginal candidosis. Br J Clin Pract 1992;46:260–263.
33. HandaVL, SticeCW. Fungal culture findings in cyclic vulvitis. Obstet Gynecol 2000;96:301–303.
34. Centers for Disease Contral and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR 2002;51:47.
35. SobelJD, ChaimW, NagappanV, LeamanD. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003;189:1297–1300.
36. GiulianoA, LewisF Jr., HadleyK, BlaisdellFW. Bacteriology of necrotizing fasciitis. Am J Surg 1977;134:52–57.
37. PessaME, HowardRJ. Necrotizing fasciitis. Surg Gynecol Obstet 1985;161:357–361.
38. SudarskyLA, LaschingerJC, CoppaGF, SpencerFC. Improved results from a standardized approach in treating patients with necrotizing fasciitis. Ann Surg 1987;206:661–665.
39. BrookI, FrazierEH. Clinical and microbiological features of necrotizing fasciitis. J Clin Microbiol 1995;33:2382–2387.

References

1. EngTR, ButlerWT (eds.). The Hidden Epidemic: Confronting Sexually Transmited Diseases. Committee on Prevention and Control of Sexually Transmitted Diseases. Washington, DC: Institute of Medicine National Academy Press, 1997.
2. CatesW, American Social Health Panel. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. Sex Transm Dis 1999;26(Suppl):S2–S7.
3. WeinstockH, BermanS, CatesW Jr. Sexually transmitted diseases among American youth: Incidence and prevealence estimates, 2000. Perspect Sex Reprod Health 2004;36:1–10.
4. ChessonHW, BlandfordJM, GiftTL, et al. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 2004;36:1–20.
5. World Health Organization. Sexually Transmitted Infections. Geneva: World Health Organization, 2013 (http://www.who.int/mediacentre/factsheets/fs110/en/, accessed 26 February 2014).
6. Centers for Disease Control and Prevention. Summary of notifiable diseases: United States 2009. MMWR 2011;58:1–117.
7. BermanSM, HeinK. Adolescents and sexually transmitted diseases. In HolmesKK, SparlingPF, MardhP-A, et al. (eds.) Sexually Transmitted Diseases. New York: McGraw-Hill, 1999, pp. 129–142.
8. CatesW Jr. Epidemiology and control of sexually transmitted diseases: strategic evaluation. Infect Dis Clin North Am 1987;1:1–23.
9. OverM, PiotP. HIV infection and sexually transmitted disease. In JamisonDT, MosleyWH, MeashamAR, BobadillaJL (eds.) Disease Control Priorities in Developing Countries. New York: Oxford University Press, 1993, pp. 455–527.
10. MeyerTF. Pathogenic Neisseriae: complexity of pathogen–host cell interplay. Clin Infect Dis 1999;28:433–441.
11. HookEW, HandsfieldHH. Gonococcal infections in adults. In HolmesKK, SparlingPF, MardhP-A, et al. (eds.) Sexually Transmitted Diseases. New York: McGraw-Hill, 1999, pp. 451–466.
12. SweetRL, GibbsRS. Infectious Diseases of the Female Genital Tract, Ch. 5: Sexually transmitted diseases. Philadelphia, PA: Lippincott Williams & Wilkins, 2008. pp. 51–79.
13. BarlowD, PhillipsI. Gonorrhea in women: diagnostic clinical and laboratory aspects. Lancet 1978;i:761.
14. SweetRL, GibbsRS. Atlas of Infectious Diseases of the Female Genital Tract. Philadelphia, PA: Lippincott, Williams & Wilkins, 2004.
15. SuleimanSA, GrimesEM, JonesHS. Disseminated gonococcal infections. Obstet Gynecol 1983;61:48–51.
16. HolmesKK, CountsGW, BeatyHN. Disseminated gonococcal infection. Ann Intern Med 1971;74;979–993.
17. DevinePA. Extraplevic manifestations of gonorrhea. Primary Care Update Obstet Gynecol 1998;5:233–237.
18. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010: gonococcal infections. MMWR 2010;59(RR-12):49–56.
19. US Preventive Services Task Force. Screening for gonorrhea: recommendation statement. Ann Fam Med 2005;3:263–267.
20. Centers for Disease Control and Prevention. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR 2007;56:332–336.
21. Centers for Disease Control and Prevention. Cephalosporin susceptibility among Neisseria gonorrhoeae isolates: United States 2000–2010. MMWR 2011;60:873–877.
22. CatesW Jr., WasserheitJN. Genital chlamydial infections: epidemiology and reproductive sequelae. Am J Obstet Gynecol 1991;164:1771–1781.
23. WashingtonAE, JohnsonRE, SandersLL. Chlamydia trachomatis infections in the United States: what are they costing us? JAMA 1987;157:2070–2072.
24. GhysPD, FransenK, DialloMO, et al. The association between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Côte d'Ivoire. AIDS 1997;11:85–93.
25. GraystonJT. Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis 1992;15:757–763.
26. KuoCC, ShorA, CampbellLA, et al. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993;167:841–849.
27. SchachterJ. Biology of Chlamydia trachomatis. In HolmesKK, SparlingPF, MardhP-A, et al. (eds.) Sexually Transmitted Diseases. New York: McGraw-Hill, 1999, pp. 391–405.
28. LyckeE, LowhagenG-B, HallagenG, et al. The risk of transmission of genital Chlamydia trachomatis infection is less frequent than that of Neisseria gonorrhoeae infection. Sex Trans Dis 1980;7:6–10.
29. StammWE. Chlamydia trachomatis infections of the adult. In HolmesKK, SparlingPF, MardhP-A, et al. (eds.) Sexually Transmitted Diseases. New York: McGraw-Hill, 1999, pp. 407–422.
30. MardhP-A. Is Europe ready for STD screening?Genitourin Med 1997;73:96–98.
31. KatzBP. Declining prevalence of chlamydial infection among adolescent girls. Sex Transm Dis 1996;23:226–229.
32. BatteigerBE, TuW, OfnerS, et al. Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis 2010;201(Suppl 2):178.
33. OhMK, CloudCA, BakerSL, et al. Chlamydial infection and sexual behavior in young pregnant teenagers. Sex Transm Dis 1993;20:45–50.
34. SaltzGR. Chlamydia trachomatis cervical infections in female adolescents. J Pediatr 1981;98:981.
35. SchachterJ, StonerE, MoncodaJ. Screening for chlamydial infections in women attending Family Planning Clinics: evaluations of presumptive indicators for therapy. West J Med 1983;138:375–379.
36. SchachterJ. Chlamydia infections (3 parts). N Engl J Med 1978;298:428–435, 490–495, 540–549.
37. SweetRL, GibbsRS. Infectious Diseases of the Female Genital Tract, Ch. 3: Chlamydial infection. Philadelphia, PA: Lippincott Williams & Wilkins, 2009, pp. 18–40.
38. BrunhamR. Epidemiological and clinical correlates of C. trachomatis and N. gonorrhoeae infection among women attending an STD clinic. Clin Res 1981;29:47A.
39. StammWE, WagnerKF, AnselR, et al. Causes of the acute urethral syndrome in women. N Engl J Med 1980;303:409–415.
40. WiesenfeldHC, HillierSL, KrohnMA, et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol 2002;100:456–463.
41. CatesW Jr., RolfsRT, AralSO. Sexually transmitted diseases, pelvic inflammatory disease, and infertility: an epidemiologic update. Epidemiol Rev 1990;12:199–200.
42. SweetRL. Microbiologic etiology of acute pelvic inflammatory disease. In SweetRL, LandersDV (eds.) Pelvic Inflammatory Disease, Springer-Verlag, 1996, pp. 19–48.
43. MardhP-A, RipaKT, SvenssonL, et al. Chlamydia trachomatis in patients with acute salpingitis. N Engl J Med 1977;296:1377–1379.
44. PattonDL, MooreDE, SpadoniLR, et al. A comparison of the fallopian tube's response to overt and silent salpingitis. Obstet Gynecol 1989;73:622–630.
45. Muller-SchoopJW, WangS-P, MunzingerJ, et al. Chlamydia trachomatis as a possible cause of peritonitis and perihepatitis in young women. BMJ 1978;1:1022–1024.
46. MoneyDM, HawesSE, EschenbachDA, et al. Antibodies to the Chlamydia 60 kd heat-shock protein are associated with laparoscopically confirmed perihepatitis. Am J Obstet Gynecol 1997;176:870–877.
47. ThygesonP, MengertWF. The virus of inclusion conjunctivitis: further observations. Arch Ophthalmol 1936;15:377–410.
48. MordhorstCH, DawsonC. Sequelae of neonatal inclusion conjunctivitis and associated disease in parents. Am J Ophthalmol 1971;71:861–867.
49. WagerGP, MartinDH, KoutskyL, et al. Puerperal infectious morbidity: relationship to route of delivery and to antepartum Chlamydia trachomatis infection. Am J Obstet Gynecol 1980;138:1028–1033.
50. PlummerFA, LagaM, BrunhamRC, et al. Postpartum upper genital tract infections in Nairobi, Kenya. Epidemiology, etiology and risk factors. J Infect Dis 1987;156:92–97.
51. SweetRL, LandersDV, WalkerC, SchachterJ. Chlamydia trachomatis infection and pregnancy outcome. Am J Obstet Gynecol 1987;156:824–833.
52. MollerBR, AhronsS, LaurinJ, et al. Pelvic infection after elective abortion associated with Chlamydia trachomatis. Obstet Gynecol 1982;59:210–213.
53. Centers for Disease Control and Prevention. Guidelines for the Laboratory Diagnosis of Gonorrhea, Chlamydia and Syphilis. Atlanta, GA: Centers for Disease Control and Prevention, 2009.
54. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010: chlamydial infections. MMWR 2010;59:44–48.
55. SchachterJ, CherneskyMA, WillisDE, et al. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections. Sex Transm Dis 2005;32:725–728.
56. DoshiJS, PowerJ, AllenE. Acceptibility of Chlamydia screening using self-taken vaginal swabs. Int J STD AIDS 2008;19:507–509.
57. US Preventive Services Task Force. Screening for Chlamydial Infection. Rockville, MD: US Preventive Services Task Force, 2007.
58. LauCY, QureshiAK. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis 2002;29:497–502.
59. CrombleholmeWR, SchachterJ, GrossmanM, LandersDV, SweetRL. Amoxicillin therapy for Chlamydia trachomatis in pregnancy. Obstet Gynecol 1990;75:752–756.
60. Centers for Disease Control and Prevention. Primary and secondary syphilis: United States 1998. MMWR 1999;48:873–878.
61. Centers for Disease Control. Continuing increase in infectious syphilis: United States. MMWR 1988;37:35–38.
62. Centers for Disease Control and Prevention. Congenital syphilis: United States, 1998. MMWR 1999;48:757–761.
63. Centers for Disease Control and Prevention. Primary and secondary syphilis: United States 2000–2001. MMWR 2002;51:971.
64. AralSO, HolmesKK. Social and behavioral determinants of the epidemiology of STDs: industrialized and the developing countries. In HolmesKK, SparlingPF, MardhP-A, et al. (eds.) Sexually Transmitted Diseases. New York: McGraw-Hill, 1999, pp. 39–76.
65. Centers for Disease Control and Prevention. 2009 Sexually Transmitted Diseases Surveillance. Atlanta, GA: Centers for Disease Control and Prevention (http://www.cdc.gov/std/stats09/default.htm, accessed 26 February 2014).
66. Centers for Disease Control. Syphilis trends in the United States. MMWR 1981;31:441–444.
67. TramontEC. Syphilis in adults: from Christopher Columbus to Sir Alexander Fleming to AIDS. Clin Infect Dis 1995;21:1361–1371.
68. ChapelTA. The signs and symptoms of secondary syphilis. Sex Trans Dis 1980;7:161–164.
69. YoumansJB. Syphilis and other venereal diseases. Med Clin North Am 1964;48:571–824.
70. KollmanTR, DobsonS. Syphilis. In RemingtonJS, KleinJO (eds.) Infectious Diseases of the Fetus and Newborn Infant. Philadelphia, PA: Saunders, 2011, pp. 524–563.
71. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010: syphilis. MMWR 2010;59(RR-12):26–38.
72. World Health Organization. Sexually Transmitted Diseases: Three Hundred and Thirty-Three Million New, Curable Cases in 1995 [Press Release WHO/64]. Geneva: World Health Organization, 1995.
73. FloodJM, SafrinSK, BolanGA, et al. Multistrain outbreak of chancroid in San Francisco, 1989–1991. J Infect Dis 1993;167:1106–1111.
74. RonaldAR, AlbrittonW. Chancroid and Haemophilus ducreyi. In HolmesKK, SparlingPF, MardhP-A, et al. (eds.) Sexually Transmitted Diseases. New York: McGraw-Hill, 1999 pp. 515–523.
75. DicarloRP. Chancroid epidemiology in New Orleans men. J Infect Dis 1995;173:446–452.
76. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010: chancroid. MMWR 2010;59(RR-12):19–20.
77. PlummerFA. Clinical and microbiologic studies of genital ulcers in Kenyan women. Sex Trans Dis 1985;12:193.
78. LockettAE. Serum-free media for the isolation of Haemophilus ducreyi. Lancet 1991;338:326.
79. OrleKA. Simultaneous PCR detection of Haemophilus ducreyi, Treponema pallidum and herpex simplex virus types 1 and 2 from genital ulcers. J Clin Microbiol 1996;34:49–54.
80. PerinePL, StammWR. Lymphogranuloma venereum. In HolmesKK, SparlingPF, MardhP-A, et al. (eds.) Sexually Transmitted Diseases. New York: McGraw-Hill, 1999, pp. 423–432.
81. SchachterJ, SmithDE, DawsonCR, et al. Lymphogranuloma venereum. I. Comparison of the Frei test, complement fixation test and isolation of the agent. J Infect Dis 1969;120:372–375.
82. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010: lymphogranuloma venereum. MMWR 2010;59(RR-12):26.
83. O'FarrellN. Donovanosis. In HolmesKK, SparlingPF, MardhP-A, et al. (eds.) Sexually Transmitted Diseases. New York: McGraw-Hill, 1999, pp. 525–531.
84. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010: granuloma inguinale. MMWR 2010;59(RR-12):25–26.
85. HolmesKK, MardhP-A (eds.) International Perspectives on Neglected Sexually Transmitted Diseases. Washington, DC: Hemisphere Publishing, 1983, pp. 205–217.
86. IMS Health. National Disease and Therapeutic Index. Parsippany, NJ: IMS Health, 2013 (https://web01.imshealth.com/ndti/ndtilogin.aspx, accessed 26 February 2014).
87. Centers for Disease Control and Prevention. Seroprevalence of herpes simplex virus type 2 among persons aged 14–49 years: United States, 2005–2008. MMWR 2010;59:626–629.
88. XuF, MarkowitzLE, GottliebSS, et al. Seroprevalence of herpes simplex virus type 1 and type 2 in pregnant women in the United States. Am J Obstet Gynecol 2007;196:43.e1–43.e6.
89. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010: genital HSV infection. MMWR 2010;59(RR-12):20–25.
90. TronsteinE, JohnstonC, HuangM-L, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic periods with HSV-2 infection. JAMA 2011;308:1441–1449.
91. BrownZA, SelkeS, ZehJ, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997;337:509–515.
92. ArvinAM, WhitleyRJ. Herpes simplex virus infection. In RemingtonJS, KleinJV (eds.) Infectious Diseases of the Fetus and Newborn Infant. Philadelphia, PA: Saunders, 2001, pp. 425–446.
93. SheffieldJS, HollierLM, HillJB, et al. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systemic review. Obstet Gynecol 2003;102:1396–1403.
94. American Congress of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 82: management of herpes in pregnancy. Obstet Gynecol 2007;109:1489–1498.
95. CotchMF, PastorekJG III, NugentRP, et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. The vaginal infections and preterm study group. Sex Transm Dis 1997;24:353–360.
96. LagaM, ManokaA, KivuvuM, et al. Nonulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993;7:95–102.
97. GardnerH, DukesCD. Haemophilus vaginalis vaginitis: a newly defined specific infection previously classified “nonspecific” vaginitis. Am J Obstet Gynecol 1955;69:962.
98. SweetRL, GibbsRS. Infectious Diseases of the Female Genital Tract, Ch. 11: Infectious vulvovaginitis. Philadelphia, PA: Lippincott, Williams & Wilkins, 2009, pp. 96–206.
99. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010: trichomoniasis. MMWR 2010;59(RR-12):58–60.
100. MillerWC, SwygardH, HobbsMM, et al. The prevalence of trichomoniasis in young adults in the United States. Sex Transm Dis 2005;32:593–598.
101. van der PolPB, WilliamsJA, OrrDP, et al. Prevalence, incidence, natural history and response to treatment of Trichomonas vaginalis infection among adolescent women. J Infect Dis 2005;192:2039–2044.
102. SuttonM, SternbergM, KoumansEH, et al. The prevalence of Trichomonas vaginalis infection among reproductive age women in the United States 2001–2004. Clin Infect Dis 2007;45:1319–1326.
103. AllsworthJE, RaftnerJA, PeipertJF. Trichomoniasis and other sexually transmitted infections: results from the 2001–2004 National Health and Nutrition Examination Surveys. Sex Transm Dis 2009;36:738–744.
104. HardyPH, NellEE, SpenceMR, et al. Prevalence of six sexually transmitted disease agents among pregnant inner city adolescents and pregnancy outcome. Lancet 1984;8:333.
105. MasonPR, BrownI. Trichomonas in pregnancy. Lancet 1980;11:1025.
106. KlebanoffMA, CareyJC, HauthJC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001;345:487–493.
107. MullerM. LossickJG, GorrellTE, et al. In vitro susceptibility of Trichomonas vaginalis to metronidazole and treatment outcome in vaginal trichomoniasis. Sex Trans Dis 1988;15:17.
108. Platts-MillsTAE, ReinMF. Scabies. In HolmesKK, SparlingPF, MardhP-A, et al. (eds.) Sexually Transmitted Diseases, New York: McGraw-Hill, 1999, pp. 645–650.
109. Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines 2010: scabies. MMWR 2010;59:89–90.
110. OrielJD. Ectoparasites. In HolmesKK, MardhP-A (eds.) International Perspectives on Neglected Sexually Transported Diseases. Washington, DC: Hemisphere Publishing, 1983, pp. 131–138.
111. Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines 2010: pediculosis pubis. MMWR 2010;59(RR-12):88–89.
112. KwittenJ. Molluscum contagiosum: some new histologic observations. Mt Sinai J Med NY 1980;47:583–588.
113. BrownST, NalleyJF, KrausSJ. Molluscum contagiosum. Sex Transm Dis 1981;8:227–234.
114. KoutskyLA, KiviatNB. Genital human papillomavirus. In HolmesKK, SparlingPF, MardhP-A, et al. (eds.) Sexually Transmitted Diseases. New York: McGraw-Hill, 1999, pp. 347–359.
115. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 1995. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services, 1996.
116. Institute of Medicine Committee on Prevention and Control of Sexually Transmitted Diseases. The Hidden Epidemic: Confronting Sexually Transmitted Diseases. Washington, DC: National Academy Press, 1997.
117. GallSA. Human papillomavirus infection. In MeddPD, HagerWD, FaroS (eds.) Protocols for Infectious Diseases in Obstetrics and Gynecology. Malden, MA: Blackwell Science, 2000, pp. 380–389.
118. InsingaRP, DasbachEJ, MyersER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003;36:1397–1403.
119. KoutskyLA, GallowayDA, HolmesKK. Epidemiology of genital papillomavirus infection. Epidemiol Rev 1988;10:122–163.
120. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010: cervical cancer screening for women who attend STD clinics or have a history of STDs. MMWR 2010;59(RR-12):70–78.
121. WinerRL, LeeS-K, HughesJP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218–226.
122. HalpertR, FruchterRG, SedlisA, et al. Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet Gynecol 1986;68:251–258.
123. GarryR, JonesR. Relationship between cervical condylomata, pregnancy and subclinical papillomavirus infection. J Reprod Med 1985;30:393–396.
124. WernessBA. Role of the human papillomavirus oncoproteins in transformation and carcinogenic progression. In DeVitaJT (ed.) Important Advances in Oncology. Philadelphia, PA: Lippincott, 1991, p. 3.
125. BristowRE, MontzFJ. Human papillomavirus: molecular biology and screening applications in cervical neoplasia: a primer for primary care physicians. Prim Care Update Obstet Gynecol 1995;5:238–246.
126. BeutnerKR, WileyDJ, DouglasJM, et al. Genital warts and their treatment. Clin Infect Dis 1999;28(Suppl):S37–S56.
127. ChamberlainMJ, ReynoldsAL, YeomenWB. Toxic effects of podophyllin application in pregnancy. BMJ 1972;3:391–392.

References

1. Centers for Disease Control and Prevention. 2007 National Hospital Discharge Survey. Atlanta, GA: Centers for Disease Control and Prevention, 2013 (http://www.cdc.gov/nchs/nhds.htm, accessed 26 February 2014).
2. IMS Health. IMS Health Report, 1966–2009. Parsippany, NJ: IMS Health, 2010.
3. WashingtonAE, KatzP. Cost of and payment source for pelvic inflammatory disease. Trends and projections, 1983 through 2000. JAMA 1991;266:2565–2569.
4. Soper, DE, BrockwellNJ, DaltonHP, JohnsonD. Observations concerning the microbial etiology of acute salpingitis. Am J Obstet Gynecol 1994;170:1008–1014.
5. SweetRL, DraperDL, SchachterJ, et al. Microbiology and pathogenesis of acute salpingitis as determined by laparoscopy: what is the appropriate site to sample?Am J Obstet Gynecol 1980;138:985–989.
6. EschenbachDA, BuchananTM, PollackHM, et al. Polymicrobial etiology of acute pelvic inflammatory disease. N Engl J Med 1975;293:166–171.
7. KirshonB, FaroS, PhillipsLE, PruettK. Correlation of ultrasonography and bacteriology of the endocervix and posterior cul-de-sac of patients with severe pelvic inflammatory disease. Sex Transm Dis 1988;15:103–107.
8. FaroS, MartensM, MaccatoM, HammillH, PearlmanM. Vaginal flora and pelvic inflammatory disease. Am J Obstet Gynecol 1993;169:470–474.
9. NessRB, KipKE, HillierSl, et al. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol 2005;162:585–590.
10. NessRB, HillierS, KipKE, et al. Bacterial vaginosis and the risk of pelvic inflammatory disease. Obstet Gynecol 2004;104:761–769.
11. FornaF, GulmezogluAM. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev 2003;(2):CD000218.
12. KeithLG, BergerHS, EdelmanDA, et al. On the causation of pelvic inflammatory disease. Am J Obstet Gynecol 1984;149:215–224.
13. HammondTL, HankinsGD, SnyderRR. Transvaginal-peritoneal migration of Trichomonas vaginalis as a cause of ascites: a report of two cases. J Reprod Med 1990;35:179–191.
14. KeithLG, FribergJ, FullanN, BaileyR, BergerGS. The possible role of Trichomonas vaginalis as a vector for the spread of other pathogens. Int J Fert 1986;31:272–277.
15. GravesA, GardnerWA. Pathogenicity of Trichomonas vaginalis. Clin Obstet Gynecol 1993;36:145–152.
16. PaisarntatiwongR, BrockmanS, ClarkeL, et al. The relationship of vaginal trichomoniasis and pelvic inflammatory disease among women colonized with Chlamydia trachomatis. Sex Transm Dis 1995;22:344–347.
17. BrunhamRG, PaavonenJ, StevensCE, et al. Mucopurulent cervicitis: the ignored counterpart in women of urethritis in men. N Engl J Med 1984;311:1–6.
18. EckertLO, HawesSE, Wolner-HanssenPK, et al. Endometritis: the clinical-pathologic syndrome. Am J Obstet Gynecol 2002;186:690–695.
19. WiessenfeldHC, SweetRL, NessRB, et al. Comparison of acute and subclinical pelvic inflammatory disease. Sex Transm Dis 2005;32:400–405.
20. Wolner-HanssenOK, MardhPA, SvenssonL, WestromL. Laparoscopy in women with chlamydial infection and pelvic pain: a comparison of patients with and without salpingitis. Obstet Gynecol 1983;61:299–303.
21. SimmsI, WarburtonF, WeströmL. Diagnosis of pelvic inflammatory disease: time for a rethink. Sex Transm Infect 2003;79:491–494.
22. YudinMH, HillierSL, WiesenfeldHC, et al. Vaginal polymorphonuclear leukocytes and bacterial vaginosis as markers for histologic endometritis among women without symptoms of pelvic inflammatory disease. Am J Obstet Gynecol 2003;188:318–323.
23. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010: pelvic inflammatory disease. MMWR 2010;59(RR-12):63–66.
24. PaavonenJ, AineR, TeilsalaK, et al. Chlamydial endometritis. J Clin Path 1985;38:726–732.
25. CaccitoreB, LeminenA, Ingman-FribergS, YlöstaloP, PaavonenJ. Transvaginal sonographic findings in ambulatory patients with suspected pelvic inflammatory disease. Obstet Gynecol 1992;80:912–916.
26. CushingC. A contribution to the study of pelvic abscess. Buffalo Med Surg J 1888–1889;28:369–379.
27. TaipaleP. TarjanneH, YlöstaloP. Transvaginal sonography in suspected pelvic inflammatory disease. Ultrasound Obstet Gynecol 1995;6:430–434.
28. Timor-TritschIE, RottemS. Transvaginal ultrasonographic study of the fallopian tube. Am J Obstet Gynecol 1987;70:424–428.
29. Timor-TritschIE, RottemS. Transvaginal Sonography 2nd edn. New York: Elsevier Science, 1991, pp. 131–144.
30. TanNJ, RajanVS, PangR, SngEH. Gentamicin in the treatment of infections due to penicillinase-producing gonococci. Br J Vener Dis 1980;56:394–396.
31. BowieW, RonaldAR, KrywulakW, CatesCY, BoutrosP. Gentamicin in the treatment of gonorrhoea in females. Br J Vener Dis 1974;50:208–211.
32. PearlmanMD, FaroS, RiddleG, TortoleroG. In vitro synergy of clindamycin and aminoglycosides against Chlamydia trachomatis. Antimicrob Agents Chemo 1990;34:1399–1401.
33. HaggertyCL, NessRB. Newest approaches to treatment of pelvic inflammatory disease: A review of the recent clinical trials. Clin Infect Dis 2007;44:953–960.
34. MartensMG, GordonS, YarboroughDR, et al. Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. Ambulatory PID Research Group. South Med J 1993;86:604–610.
35. HemsellDL, MartensMG, FaroS, GallS, McGregorJA. A multicenter study comparing intravenous meropenem with clindamycin plus gentamicin for the treatment of acute gynecologic and obstetric pelvic infections in hospitalized women. Clin Infect Dis 1997;24(Suppl 2):S222–S230.
36. NessRB, SoperDE, HolleyRI, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the PID Evaluation and Clinical Health (PEACH) randomized trial. Am J Obstet Gynecol 2002;186:929–937.
37. HosenfeldCB, WorkowskiKA, BermanS, et al. Repeat infection with chlamydia and gonorrhea among females: a systematic review of the literature. Sex Transm Dis 2009;36:478–489.
38. HillisSD, OwensLM, MarchbanksPA, et al. Recurrent chlamydial infections increase the risk of hospitalization for ectopic pregnancy and pelvic inflammatory disease. Am J Obstet Gynecol 1997;176:103–107.

References

1. GreeneWC. The molecular biology of human immunodeficiency virus type 1 infection. N Engl J Med 1991;324:308–317.
2. LevyJA. HIV and the Pathogenesis of AIDS, 2nd edn. Washington, DC: American Society for Microbiology, 1998.
3. FauciAS, LaneHC. HIV disease: AIDS and related disorders. In BraunwaldE, FauciAS, Kasper, HauserSL, LongoDL, JamesonDL (eds.) Harrison's Principles of Internal Medicine. New York: McGraw Hill, 2001, pp. 1852–1913.
4. PrinsM, MeyerL, HessolNA. Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras. AIDS 2005;19:357–370.
5. FarzadeganH, HooverDR, AstemborskiJ, et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998;352:1510–1514.
6. GandhiM, BacchettiP, MiottiP, et al. Does patient sex affect human immunodeficiency virus levels?Clin Infect Dis. 2002;35:313–322.
7. SterlingTR, VlahovD, AmsterborskiJ, et al. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001;344:720–725.
8. KourtisAP, DuerrA. Prevention of perinatal HIV transmission: a review of novel strategies. Expert Opin Invest Drugs 2003;12:1535–1544.
9. Centers for Disease Control and Prevention. HIV Surveillance Report, 2009, Vol. 21. Atlanta, GA: Centers for Disease Control and Prevention, 2011 (http://www.cdc.gov/hiv/topics/surveillance/resources/reports/, accessed 21 November 2013).
10. Centers for Disease Control and Prevention. Heterosexual transmission of HIV–29 states, 1999–2002. MMWR 2004;53:125–129.
11. Centers for Disease Control and Prevention. Diagnoses of HIV/AIDS: 32 States, 2000–2003. MMWR 2004;53:1106–1110.
12. LaineC, MarksonLE, McKeeLJ, et al. The relationship of clinic experience with advanced HIV and survival of women with AIDS. AIDS 1998;12:417–424.
13. GeboKA, FleishmanJA, ConviserR, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr 2005;38:96–103.
14. PadianNS, ShiboskiSC, JewellNP. Female-to-male transmission of human immunodeficiency virus. JAMA 1991;266:1664–1667.
15. ClemetsonDB, MossGB, WillerfordDM, et al. Detection of HIV DNA in cervical and vaginal secretions. Prevalence and correlates among women in Nairobi, Kenya. JAMA 1993;269:2860–2864.
16. CampsmithML, RhodesPH, HallI, et al. Undiagnosed HIV prevalance among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr 2010;53:619–624.
17. BransonBM, HandsfieldHH, LampeMA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR 2006;55(RR-14):1–17.
18. MillenJC, ArbelaezC, WalenskeyRP. Implications and impact of the new US Centers for Disease Control and Prevention HIV testing guidelines. Curr Infect Dis Rep 2008;10:157–163.
19. Anon. Advancing HIV prevention: new strategies for a changing epidemic–United States, 2003. Ann Pharmacother 2003;37:935.
20. WesolowskiLG, MacKellarDA, FacenteSN, et al. Post-marketing surveillance of OraQuick whole blood and oral fluid rapid HIV testing. AIDS 2006;20:1661–1666.
21. JongeriusJM, SjerpsM, CuijpersHT, et al. Validation of the NucliSens Extractor combined with the AmpliScreen HIV version 1.5 and HCV version 2.0 test for application in NAT minipool screening. Transfusion 2002;42:792–797.
22. TsibrisAMN, HirschMS. Antiretroviral therapy for HIV infection. In BennettJE, DolinR (eds.) Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th edn. Philadelphia, PA: Elsevier Church-Livingstone, 2010, pp. 1853–1854.
23. MocroftA, GillMJ, DavidsonW, et al. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defic Syndr 2000;24:475–482.
24. CollazosJ, AsensiV, CartonJA. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. AIDS 2007;21:835–843.
25. CurrierJS, SpinoC, GrimesJ, et al. Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The AIDS Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr 2000;24:316–324.
26. MehtaSA, AhmedA, LavertyM, et al. Sex differences in incidence of peripheral neuropathy among Kenyans initiating antiretroviral therapy. Clin Infect Dis 2011;53:490–496.
27. Bersoff-MatchaSJ, MillerWC, AbergJA. Sex differences in nevirapine rash. Clin Infect Dis 2001;32:124–129.
28. SternJO, RobinsonPA, LoveJ, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003;34(Suppl 1):S21–S33.
29. GervasoniC, RidolfoAL, TrifiroG, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999;13:465–471.
30. ClarkRA, SquiresKE. Gender-specific considerations in the antiretroviral management of HIV-infected women. Expert Rev Anti Infect Ther 2005;3:213–227.
31. CazanaveC, DuponM, Lavignolle-AurillacV, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008;22:395–402.
32. ClarkMK, SowersMR, NicholsS, et al. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril 2004;82:1580–1586.
33. ClayPG, VossLE, WilliamsC, et al. Valid treatment options for osteoporosis and osteopenia in HIV-infected persons. Ann Pharmacothe 2008;42:670–679.
34. AIDSinfo. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. Rockville, MD: AIDSinfo, 2012 (http://aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/0, accessed 26 February 2014).
35. AIDSinfo. Guidelines for the Use of Antiretroviral Agents in HIV-1 infected Adults and Adolescents. Rockville, MD: AIDSinfo, 2013 (http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0, accessed 26 February 2014).
36. WellerS, DavisK. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002;1:CD003255.
37. Centers for Disease Control and Prevention. Condom Fact Sheet in Brief. Atlanta, GA: Centers for Disease Control and Prevention, 2013 (http://www.cdc.gov/condomeffectiveness/brief.html#Condom, accessed 21 November 2013).
38. NgBE, ButlerLM, HorvathT, et al. Population-based biomedical sexually transmitted infection control interventions for reducing HIV infection. Cochrane Database Syst Rev 2011;3:CD001220.
39. Van DammeL, RamjeeG, AlaryM, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002;360:971–977.
40. FeldblumPJ, AdeigaA, BakareR, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008;3:e1474.
41. Van DammeL, GovindenR, MirembeFM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008;359:463–472.
42. Abdool KarimSS, RichardsonBA, RamjeeG, et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 2011;25:957–966.
43. McCormackS, RamjeeG, KamaliA, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010;376:1329–1337.
44. Abdool KarimQ, Abdool KarimSS, FrohlichJA, et al. Effectiveness and safety of tenofovir gel, and antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168.
45. GrantRM, LamaJR, AndersonPL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587–2599.
46. BaetenJ, CelumC. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the partners PrEP study. In Sixth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention Rome, July, 2011, Abst MOAX0106.
47. ThigpenMC, KebaabetswePM, SmithDK, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 Study. In Sixth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention Rome, July, 2011, Abst WELBC01.
48. Anon. Seven Days: 30 September–6 October 2011. The news in brief. Nature 2011;478:10–11.
49.[No authors listed]. Early end for FEM-PrEP HIV prevention trial. AIDS Patient Care STDS 2011;25:383.
50. Centers for Disease Control and Prevention. Pre-Exposure Prophylaxis (PrEP). Atlanta, GA: Centers for Disease Control and Prevention, 2013 (http://www.cdc.gov/hiv/prevention/research/prep/ accessed 26 February 2014).
51. LimaVD, JohnstonK, HoggRS, et al. Expanded access to highly active antiretroviral therapy: A potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 2008;198:59–67.
52. Donnell, D, BaetenJM, KiarieJ, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010;375:2092–2098.
53. CohenMS, ChenYQ, McCauleyM, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493–505.
54. MontanerJS, LimaVD, BarriosR, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010;376:532–539.
55. SmithDK, GrohskopfLA, BlackRJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the US Department of Health and Human Services. MMWR 2005;54(RR-2):1–20.
56. Centers for Disease Control and Prevention. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. MMWR 1998;47(RR-7):1–33.
57. BarkanSE, MelnickSL, Preston-MartinS, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998;9:117–125.
58. SmithDK, WarrenDL, VlahovD, et al. Design and baseline participant characteristics of the Human Immunodeficiency Virus Epidemiology Research (HER) Study: a prospective cohort study of human immunodeficiency virus infection in US women. Am J Epidemiol 1997;146:459–469.
59. CejtinHE. Gynecologic issues in the HIV-infected woman. Obstet Gynecol Clin North Am 2003;30:711–729.
60. Ahdieh-GrantL, LiR, LevineAM, et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. JNCI 2004;96:1070–1076.
61. HeardI, PalefskyJM, KazatchkineMD. The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antivir Ther 2004;9:13–22.
62. MaimanM, WattsDH, AndersenJ, et al. Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: a randomized trial. Obstet Gynecol 1999;94:954–961.
63. WrightTC, Jr., SubbaraoS, EllerbrockTV, et al. Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol 2001;184:279–285.
64. ConleyLJ, EllerbrockTV, BushTJ, et al. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002;359:108–113.
65. JamiesonDJ, ParamsothyP, Cu-UvinS, DuerrA. Vulvar, vaginal, and perianal intraepithelial neoplasia in women with or at risk for human immunodeficiency virus. Obstet Gynecol 2006;107:1023–1028.
66. PhelpsRM, SmithDK, HeiligCM, et al. Cancer incidence in women with or at risk for HIV. Int J Cancer 2001;94:753–757.
67. GrubertTA, ReindellD, KastnerR, et al. Rates of postoperative complications among human immunodeficiency virus-infected women who have undergone obstetric and gynecologic surgical procedures. Clin Infect Dis 2002;34:822–830.
68. SewellCA, DerrR, AndersonJ. Operative complications in HIV-infected women undergoing gynecologic surgery. J Reprod Med 2001;46:199–204.
69. FranzJ, JamiesonDJ, RandallH, SpannC. Outcomes of hysterectomy in HIV-seropositive women compared to seronegative women. Infect Dis Obstet Gynecol 2005;13:167–169.
70. DuerrA, HeiligCM, MeikleSF, et al. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: Risk factors and severity. Obstet Gynecol 2003;101:548–556.
71. JamiesonDJ, DuerrA, KleinRS, et al. Longitudinal analysis of bacterial vaginosis: findings from the HIV epidemiology research study. Obstet Gynecol 2001;98:656–663.
72. Cu-UvinS, KoH, JamiesonDJ, et al. Prevalence, incidence, and persistence or recurrence of trichomoniasis among human immunodeficiency virus (HIV)-positive women and among HIV-negative women at high risk for HIV infection. Clin Infect Dis 2002;34:1406–1411.
73. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010. MMWR Recomm Rep 2010;59(RR-12):1–116.
74. Centers for Disease Control and Prevention. US medical eligibility criteria for contraceptive use, 2010. MMRW 2010;59(RR-4):1–86.
75. HeffronR, DonnellD, ReesH, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2012;12:19–26.
76. CurtisKM, NandaK, N Kapp. Safety of hormonal and intrauterine methods of contraception for women with HIV/AIDS: a systematic review. AIDS 2009;23(Suppl 1):S55–S67.
77. BlishCA, BaetenJM. Hormonal contraception and HIV-1 transmission. Am J Reprod Immunol 2011;65:302–307.
78. MorrisonCS, TurnerAN, JonesLB. Highly effective contraception and acquisition of HIV and other sexually transmitted infections. Best Pract Res Clin Obstet Gynaecol 2009;23:263–284.
79. DuerrA, JamiesonD. Assisted reproductive technologies for HIV-discordant couples. Am J Bioeth 2003;3:45–47.
80. JamiesonDJ, SchieveL, DuerrA. Semen processing for HIV-discordant couples. Am J Obstet Gynecol 2001;185:1433–1434.

References

1. HoGY, BiermanR, BeardsleyL, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423–428.
2. CastellsagueX, MunozN. Cofactors in human papillomavirus carcinogenesis – role of parity, oral contraceptives, and tobacco smoking. JNCI Monogr 2003;20–28.
3. CastlePE, GiulianoAR. Genital tract infections, cervical inflammation, and antioxidant nutrients: assessing their roles as human papillomavirus cofactors. JNCI Monogr 2003;29–34.
4. HoGY, BurkRD, KleinS, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. JNCI 1995;87:365–371.
5. zur HausenH. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342–350.
6. TurekLP. The structure, function, and regulation of papillomaviral genes in infection and cervical cancer. Adv Virus Res 1994;44:305–356.
7. FloresER, Allen-HoffmannBL, LeeD, LambertPF. The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. J Virol 2000;74:6622–6631.
8. American Congress of Obstetricians and Gynecologists Committee on Adolescent Health Care. ACOG Committee Opinion No. 301: sexually transmitted diseases in adolescents. Obstet Gynecol 2004;104:891–898.
9. SolomonD, DaveyD, KurmanR, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114–2119.
10. FerenczyA, MitaoM, NagaiN, et al. Latent papillomavirus and recurring genital warts. N Engl J Med 1985;313:784–788.
11. ZaakD, HofstetterA, FrimbergerD, SchneedeP. Recurrence of condylomata acuminata of the urethra after conventional and fluorescence-controlled Nd:YAG laser treatment. Urology 2003;61:1011–1015.
12. TingPT, DytocMT. Therapy of external anogenital warts and molluscum contagiosum: a literature review. Dermatol Ther 2004;17:68–101.
13. MawR. Critical appraisal of commonly used treatment for genital warts. Int J STD AIDS 2004;15:357–364.
14. BeutnerKR, SpruanceSL, HoughamAJ, et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998;38:230–239.
15. BeutnerKR, TyringSK, TrofatterKF, Jr., et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998;42:789–794.
16. EdwardsL, FerenczyA, EronL, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Arch Dermatol 1998;134:25–30.
17. SauderDN, SkinnerRB, FoxTL, OwensML. Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations. Sex Transm Dis 2003;30:124–128.
18. EdwardsL. Imiquimod in clinical practice. Australas J Dermatol 1998;39(Suppl 1):S14–S16.
19. GunterJ. Genital and perianal warts: new treatment opportunities for human papillomavirus infection. Am J Obstet Gynecol 2003;189(Suppl):S3–S11.
20. WileyDJ, DouglasJ, BeutnerK, et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 2002;35(Suppl 2):S210–S224.
21. OstorAG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993;12:186–192.
22. MitchellMF, Tortolero-LunaG, WrightT, et al. Cervical human papillomavirus infection and intraepithelial neoplasia: a review. JNCI Monogr 1996;21:17–25.
23. ChangAR. Carcinoma in situ of the cervix and its malignant potential. A lesson from New Zealand. Cytopathology 1990;1:321–328.
24. JakusS, EdmondsP, DuntonC, KingSA. Margin status and excision of cervical intraepithelial neoplasia: a review. Obstet Gynecol Surv 2000;55:520–527.
25. KobakWH, RomanLD, FelixJC, et al. The role of endocervical curettage at cervical conization for high-grade dysplasia. Obstet Gynecol 1995;85:197–201.
26. WidrichT, KennedyAW, MyersTM, et al. Adenocarcinoma in situ of the uterine cervix: management and outcome. Gynecol Oncol 1996;61:304–308.
27. PoynorEA, BarakatRR, HoskinsWJ. Management and follow-up of patients with adenocarcinoma in situ of the uterine cervix. Gynecol Oncol 1995;57:158–164.
28. KoutskyLA, HolmesKK, CritchlowCW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272–1278.
29. MoscickiAB, HillsN, ShiboskiS, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995–3002.
30. MoscickiAB, ShiboskiS, BroeringJ, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998;132:277–284.
31. WoodmanCB, CollinsS, WinterH, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831–1836.
32. Vail-SmithK, WhiteDM. Risk level, knowledge, and preventive behavior for human papillomaviruses among sexually active college women. J Am Coll Health 1992;40:227–230.
33. RamirezJE, RamosDM, ClaytonL, et al. Genital human papillomavirus infections: knowledge, perception of risk, and actual risk in a nonclinic population of young women. J Womens Health 1997;6:113–121.
34. YacobiE, TennantC, FerranteJ, et al. University students' knowledge and awareness of HPV. Prev Med 1999;28:535–541.
35. DellDL, ChenH, AhmadF, StewartDE. Knowledge about human papillomavirus among adolescents. Obstet Gynecol 2000;96:653–656.
36. GerhardtCA, PongK, KollarLM, et al. Adolescents' knowledge of human papillomavirus and cervical dysplasia. J Pediatr Adolesc Gynecol 2000;13:15–20.
37. HolcombB, BaileyJM, CrawfordK, RuffinMT. Adults' knowledge and behaviors related to human papillomavirus infection. J Am Board Fam Pract 2004;17:16–31.
38. ReedBD, RuffinMT, GorenfloDW, ZazoveP. The psychosexual impact of human papillomavirus cervical infections. J Fam Pract 1999;48:110–116.
39. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59:626–629.

References

1. FaroS. Vaginal microflora. In FaroS (ed.) Sexually Transmitted Diseases in Women. Philadelphia, PA: Lippincott Williams & Wilkins, 2003, p. 98.
2. FaroS, PhillipsLE, MartensMG. Perspectives on the bacteriology of postoperative obstetric–gynecologic infections. Am J Obstet Gynecol 1988;158:694–700.
3. AroutchevaA, GaritiD, SimonM, et al. Defense factors of vaginal lactobacilli. Am J Obstet Gynecol 2001;185:375–379.
4. AroutchevaA, SimoesJA, FaroS. Antimicrobial protein produced by vaginal Lactobacillus acidophilus that inhibits Gardnerella vaginalis. Infect Dis Obstet Gynecol 2001;9:33–39.
5. MartensMG, FaroS, RiddleG. Female genital tract abscess formation in the rat. Use of pathogens including enterococci. J Reprod Med 1993;38:719–724.
6. LinL, SongJ, KimberN, et al. The role of bacterial vaginosis in infection after major gynecologic surgery. Infect Dis Obstet Gynecol 1999;7:169–174.
7. WeigeltJA, FaroS. Antimicrobial therapy for surgical prophylaxis and for intra-abdominal and gynecologic infections. Am J Surg 1998;176:1S–3S.
8. BenignoBB, EvrardJ, FaroS, et al. A comparison of piperacillin, cephalothin and cefoxitin in the prevention of postoperative infections in patients undergoing vaginal hysterectomy. Surg Gynecol Obstet 1986;163:421–427.
9. PoindexterAN, RitterM, FaroS, et al. Results of noncomparative studies of cefotetan in the treatment of obstetric and gynecologic infections. Am J Obstet Gynecol 1988;158:717–721.
10. SweetRL, RoyS, FaroS, et al. Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. The piperacillin/tazobactam study group. Obstet Gynecol 1994;83:280–286.
11. FaroS, MartensMG, HammillHA, et al. Antibiotic prophylaxis: is there a difference?Am J Obstet Gynecol 1990;162:900–907.
12. BoneRC. The pathogenesis of sepsis. Ann Intern Med 1991;115:457–469.
13. BoneRC. Why new definitions of sepsis and organ failure are needed. Am J Med 1993;95:348–350.
14. ParrilloJE. Mechanisms of disease: pathogenetic mechanisms of septic shock. N Engl J Med 1993;328:1471–1478.
15. BoneRC. Systemic inflammatory syndrome: a unifying concept of systemic inflammation. In FeinAM, AbrahamEM, BalkRA, et al. (eds.) Sepsis and Multiorgan Failure. Baltimore, MD: Williams & Wilkins, 1977, pp. 3–10.
16. FaroS. Sepsis in obstetric and gynecologic patients. In RemingtonJS, SwartzMN (eds.) Current Clinical Topics in Infectious Diseases. Maiden, MD: Blackwell Science, 1999, pp. 60–62.
17. Van AmersfoortES, Van BerkelTJ, KuiperJ. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 2003;16:379–414.
18. DinarelloCA, GelfandJA, WolffSM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993;269:1829–1835.
19. PlatzerC, MeiselCH, VogtK, et al. Up-regulation of monocytic IL-10 by tumor necrosis factor-α and cAMP-elevating drugs. Int Immunol 1995;7:517–523.
20. FukushimaR, AlexanderJW, GianottiL, OgleCK. Isolated pulmonary infection acts as a source of systemic tumor necrosis factor. Crit Care Med 1994;22:114–120.
21. MeduriGU, KohlerG, HeadleyS, et al. Inflammatory cytokines in the BAL of patients with ARDS: Persistent elevation over time predicts poor outcome. Chest 1995;108:1303–1314.
22. SauderDN, SempleJ, TruscottD, et al. Stimulation of muscle protein degradation by murine and human epidermal cytokines: relationship to thermal injury. J Invest Dermatol 1986;87:711–714.
23. CongerJD, WeilJV. Abnormal vascular function following ischemia-reperfusion injury. J Invest Med 1995;43:431–442.
24. LeviM, ten CateH, van der PolT, van DeventerSJ. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993;270:975–979.
25. Gomez-JimenezJ, SalgadoA, MourelleM, et al. l-Arginine: nitric oxide pathway in endotoxemia and human septic shock. Crit Care Med 1995;23:253–258.
26. MiyauchiT, TomobeY, ShibaR, et al. Involvement of endothelin in the regulation of human vascular tonus. Potent vasoconstrictor effect and existence in endothelial cells. Circulation 1990;81:1874–1880.
27. LivingstonDH, AppelSH, WellhausenSR, et al. Depressed interferon-γ production and monocyte HLA-DR expression after severe injury. Arch Surg 1988;123:1309–1312.
28. MillsCD, CaldwellMD, GannDS. Evidence of a plasma-mediated “window” of immunodeficiency in rats following trauma. J Clin Immunol 1989;9:139–150.
29. OpalSM, CohenJ. Clinical Gram-positive sepsis: does it fundamentally differ from Gram-negative bacterial sepsis?Crit Care Med 1999;27:1608–1616.
30. GlauserMP, ZanettiG, BaumgartnerJD, CohenJ. Septic shock: pathogenesis. Lancet 1991;338:732–736.
31. BatesDW, PruessKE, LeeTH. How bad are bacteremia and sepsis? Outcomes in a cohort with suspected bacteremia. Arch Intern Med 1995;155:593–598.
32. GeerdesHF, ZieglerD, LodeH, et al. Septicemia in 980 patients at a university hospital in Berlin: prospective studies during 4 selected years between 1979 and 1989. Clin Infect Dis 1992;15:991–1002.
33. HellmanJ, LoisellePM, TehanMM, et al. Outer membrane protein A, peptidoglycan-associated lipoprotein, and murein lipoprotein are released by Escherichia coli bacteria into serum. Infect Immun 2000;68:2566–2572.
34. RietschelET, KirikaeT, SchadeFU, et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J 1994;8:217–225.
35. TakakuwaT, EndoS, NakaeH, et al. Blood cytokine and complement levels in patients with sepsis. Res Commun Chem Pathol Pharmacol 1994;84:291–300.
36. VogelSN, HoganMM. Role of cytokines in endotoxins-mediated host responses, In JJ Oppenheim, EM Shevach (eds.) Immunophysiology. The Role of Cells and Cytokines in Immunity and Inflammation. Oxford, UK: Oxford University Press, 1990, pp. 238–258.
37. FoxES, ThomasP, BroitmanSA. Comparative studies of endotoxin uptake by isolated rat Kupffer and peritoneal cells. Infect Immun 1987;55:2962–2966.
38. RobertsJM, LarosRK II. Hemorrhagic and endotoxic shock: pathophysiologic approach to diagnosis and management. Am J Obstet Gynecol 1971;110:1041–1049.
39. SwanHJ, GanzW, ForresterJ, et al. Catheterization of the heart in man with use of a flow-directed balloon-tipped catheter. N Engl J Med 1970;283:447–451.
40. PorembkaDT. Cardiovascular abnormalities in sepsis. New Horiz 1993;1:324–341.
41. RaoPS, CavanaghD. Endotoxic shock in the primate: some effects of dopamine administration. Am J Obstet Gynecol 1982;144:61–66.
42. GoldbergLI. Dopamine: clinical uses of endogenous catecholamine. N Engl J Med 1974;291:707–710.
43. ShoemakerWC, KramHB, AppelPL, FlemingAW. The efficacy of central venous and pulmonary artery catheters and therapy based upon them in reducing mortality and morbidity. Arch Surg 1990;125:1332–1337.
44. BollaertPE, BauerP, AudibertG, et al. Effects of epinephrine on hemodynamics and oxygen metabolism in dopamine-resistant septic shock. Chest 1990;98:949–953.
45. HindsC, WatsonD. Manipulating hemodynamics and oxygen transport in critically ill patients. N Engl J Med 1995;33:1074–1075.
46. AlturaBM, GebrewoldA, BurtonRW. Failure of microscopic metarterioles to elicit vasodilator responses of acetylcholine, bradykinin, histamine, and substance P after ischemic shock, endotoxemia and trauma: possible role of endothelial cells. Microcirc Endothel Lymphat 1985;2:121–127.
47. KnuppelRA, RaoPS, CavanaughD. Septic shock in obstetrics. Clin Obstet Gynecol 1984;27:3–10.
48. DemlingRH, LalondeC, IkegamiK. Physiologic support of the septic patient. Surg Clin North Am 1994;74:637–658.
49. Fiddian-GreenRG, HaglundU, GutierrezG, ShoemakerWC. Goals for the resuscitation of shock. Crit Care Med 1993;21:525–528.
50. LevyMM, FinkMP, MarshallJC, AbrahamE, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250–1256.
51. DellingerRP, CarletJM, MasurH, for the Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858–871.